Pure Global
NCT06088199

A Study of Apremilast in Pediatric Participants in Children With Mild to Moderate Plaque Psoriasis

A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis
Amgen·Phase 3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Plaque Psoriasis
Drug/Device/Intervention
Apremilast
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Amgen
Location
Scottsdale,Scottsdale,Santa Monica,Thousand Oaks,Miami,Indianapolis,Missoula,Tulsa,Cypress,Pflugerville,Sugar Land,Mill Creek, United States of America
Timeline & enrollment
Phase
Phase 3
Start date
Oct 24, 2023
End date
Dec 17, 2026
Enrollment
50 participants
Primary outcome

Number of Participants With Treatment-emergent Adverse Events

Summary

The primary objective of this post-marketing study is to assess the safety and tolerability
 of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate
 plaque psoriasis.

ICD-10 classifications
PsoriasisLarge plaque parapsoriasisOther psoriasisSmall plaque parapsoriasisArthropathic psoriasis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06088199
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06088199 through Pure Global AI's free database. This Phase 3 trial is sponsored by Amgen and is currently Recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.